2022 International Bladder Cancer Network - Results from #20

Viewing 21-40 of 42 articles

IBCN 2022: Quality of Life in Patients with High-Grade NMIBC Undergoing Standard Versus Reduced Frequency of BCG Instillations: Results of the EAU-RF NIMBUS-Trial

IBCN 2022: γδ T Cells Involvement in Bladder Cancer

IBCN 2022: Actionable Genomic Landscapes From a Real-World Cohort of Localized Urothelial Carcinoma Patients

IBCN 2022: Matrix Metalloproteineases in Blood and Urine Can Be Potential Biomarkers for Prediction of Bladder Cancer Outcome

IBCN 2022: Low Guideline Adherence to Recommended Use of Neoadjuvant Chemotherapy in Patients With Non-Metastatic Muscle-Invasive Bladder Cancer

IBCN 2022: Assessment of Predictive Genomic Biomarkers for Response to Cisplatin-Based Neoadjuvant Chemotherapy in Bladder Cancer

IBCN 2022: Stromal Marker Fibroblast Activation Protein Drives Outcome in T1 Non-Muscle Invasive Bladder Cancer

IBCN 2022: Innovation and Novel Approach To the Treatment of NMIBC and MIBC

IBCN 2022: Abnormal Methylation of Selected Tumor Supressor Genes as Driving Factors Muscle Invasive, High Grade Bladder Cancer

IBCN 2022: Identification of Cisplatin Resistance Biomarkers for Urothelial Carcinoma by Mass Spectrometry and Tissue Microarray Analysis

IBCN 2022: Uromonitor®, BTA Stat®, Alere NMP22® BladderChek®, and UBC® Rapid Test in Comparison to Cytology as Tumor Marker for Urinary Bladder Cancer: New Results of a German Prospective Multicentre-Study

IBCN 2022: Surveillance of High-Grade Non-Muscle-Invasive Bladder Tumours Using the Xpert® Bladder Cancer Monitor: The DaBlaCa-15 Randomised Clinical Trial

IBCN 2022: Propensity Matched Comparison of Radical Cystectomy with Trimodality Therapy for Muscle Invasive Bladder Cancer: A Multi-Institutional Study

IBCN 2022: Updated Follow-up Data and Biomarker Analysis of Pre-operative Ipilimumab and Nivolumab in Locoregional Advanced Urothelial Cancer (NABUCCO)

IBCN 2022: Prospective Study on FDG-PET/CT for On-treatment Assessment of Response to Neoadjuvant or Induction Chemotherapy in Invasive Bladder Cancer

IBCN 2022: Associations Between Molecular Subtypes and Metastatic Sites in Urothelial Cancer

IBCN 2022: Single Nucleus RNA-Sequencing of Human Bladder Tumors Delineates Intra-Tumor Subtype Heterogeneity

IBCN 2022: Multi-Omic Profiling of Bladder and Ureteric Urothelium Reveals Regulatory Differences Pertinent to Urothelial Carcinoma Development Across the Urinary Tract

IBCN 2022: Predictive Value of Molecular Subtypes and APOBEC3G for Adjuvant Chemotherapy in Urothelial Bladder Cancer

IBCN 2022: Whole Genome Sequencing of 126 Early Age at Onset Bladder Cancer Patients Identifies Novel Candidate Risk Variants

1
2
3